Last reviewed · How we verify
NCT01237574: CALMET
Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease
trial testing Intervention according to the standard of care. in Liver Diseases, Alcoholic in 527 participants. Completed in 12 December 2020.
12 December 2020
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 527 |
| Start date | 23 November 2010 |
| Primary completion | 12 December 2020 |
| Estimated completion | 12 December 2020 |
| Sites | 36 locations across France |
Drugs / interventions tested
- Intervention according to the standard of care.
Conditions studied
- Liver Diseases, Alcoholic — all drugs for Liver Diseases, Alcoholic →
- Metabolic Diseases — all drugs for Metabolic Diseases →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Liver Diseases, Alcoholic or Metabolic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic alcoholic and metabolic liver diseases are the two main liver diseases in France. The long-term prognosis of these two diseases are not well known because main studies are retrospective and with only alcoholic patients. The knowledge of the natural history of these diseases should improve the management of patients with such diseases. The aim of this prospective cohort is to describe the natural history of patients with chronic liver disease due to alcohol or metabolic disease and to identify factors associated with complications of these liver diseases (cirrhosis, hepatocellular carcinoma, ascites. ..).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01237574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Diseases, Alcoholic
Currently open trials in the same condition.
- NCT06493773 — Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial · NA · recruiting
- NCT06613698 — A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Y · Phase 2 · recruiting
- NCT03308916 — Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers · NA · recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01237574 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 26 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01237574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing